{"id":"W2838357484","doi":"10.1093/annonc/mdy232","title":"Pembrolizumab for advanced prostate adenocarcinoma: findings of the KEYNOTE-028 study","year":2018,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":367,"is_retracted":false,"has_abstract":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Pembrolizumab; Response Evaluation Criteria in Solid Tumors; Internal medicine; Prostate cancer; Oncology; Clinical endpoint; Cohort; Adverse effect; Progressive disease; Cancer; Urology; Surgery; Clinical trial; Disease; Immunotherapy","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0003925452,0.0001023207,0.0003816715,0.00006760663,0.00005986268,0.000002070625,0.0001621611,0.00008253736,0.00007164196],"category_scores_gemma":[0.0001274732,0.00006747011,0.0001740908,0.0001900196,0.0003573544,0.00003707979,0.00004821135,0.00007778817,0.000002907706],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.00003277389,"about_ca_system_score_gemma":0.000268593,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.00007839741,"about_ca_topic_score_gemma":0.00006485516,"domain_scores_codex":[0.9990171,0.00005732897,0.0003797496,0.0001809093,0.000144859,0.0002200089],"domain_scores_gemma":[0.9989369,0.0001177997,0.0002266808,0.000312746,0.0003702406,0.00003565498],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"observational","study_design_scores_codex":[0.1627862,0.005687639,0.3096102,0.0006071655,0.001801713,0.00002185462,0.01726699,0.000003071825,0.2125162,0.0004071326,0.05134022,0.2379517],"study_design_scores_gemma":[0.0187813,0.04961915,0.660506,0.0001072269,0.0001623116,0.00003550561,0.001309204,0.0000145525,0.1872556,0.0003271457,0.08174423,0.0001377188],"study_design_candidate":"observational","study_design_consensus":"observational","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9912642,0.0005741762,0.00001150396,0.004775171,0.0003241608,0.001357377,0.00002248104,0.00001031998,0.001660596],"genre_scores_gemma":[0.9973448,0.00007282074,0.000159533,0.001308055,0.00009777246,0.00005085485,0.000002912105,0.00001447242,0.0009487868],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.3508958,"threshold_uncertainty_score":0.2751351,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.06985392706225708,"score_gpt":0.4013476399603873,"score_spread":0.3314937128981302,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}